Quick Answer
Adaptive Biotechnologies Corp reported Long Term Debt of $126.57 million for the year ending 2025.
- Adaptive Biotechnologies Corp showed a decrease of -4.4% in Long Term Debt from 2024 to 2025.
- This data is from Adaptive Biotechnologies Corp's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2023: $126.73 million | Q1 2024: $131.55 million | Q2 2024: $132.08 million | Q3 2024: $132.70 million | Q1 2025: $131.55 million | Q2 2025: $130.50 million | Q3 2025: $129.41 million.
- Over the full 4 years of available data (2022 to 2025), Adaptive Biotechnologies Corp's Long Term Debt has grown by 1.0%.
- Historical annual values: Fiscal year 2025: $126.57 million | Fiscal year 2024: $132.41 million | Fiscal year 2023: $130.66 million | Fiscal year 2022: $125.36 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: